Florida Hall D
6000 W Osceola Pkwy
Kissimmee, FL 34746
7:00 AM: Welcome and Introduction
7:10 AM: Where Does Allogeneic HCT Fit in the JAK Inhibitor Treatment Era?
7:30 AM: Combinations for Potential Cures in MF: Integrating Transplant with JAK Inhibitors
7:50 AM: Thoughts on Combined Modality Care in MF and Ask-the-Experts Q&A
Hematopoietic stem cell transplantation (HCT) is a potentially curative treatment option for myelofibrosis (MF); however, many patients have traditionally not been eligible for transplant. Recent developments in therapy for MF—particularly the emergence of JAK inhibitors—have increased the number of treatment options for patients with MF. These advances have also raised several questions with implications for HCT, including whether transplant-based treatment can be used in conjunction with JAK inhibitors and other emerging treatments. At PeerView’s upcoming live event at the BMT Tandem Meetings in 2017, leading experts in MF will offer their clinical insights on the evolving role of HCT in the modern JAK inhibitor–based treatment era for patients with MF and discuss practical considerations of eligibility, impact of JAK inhibitor therapy on post-transplant outcomes, and optimal combination and sequencing of the two modalities in appropriate patient candidates.
Upon completion of this activity, participants should be better able to:
This activity will be designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the care of patients with MF.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test and evaluation form.
Release and Expiration Date: February 24, 2017
Time to Complete: 60 minutes
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Nicolaus Kröger, MD
Professor of Medicine
Department of Stem Cell Transplantation
University Hospital Hamburg-Eppendorf
Vikas Gupta, MD, FRCP, FRCPath
Director, The Elizabeth and Tony Comper MPN Program
Princess Margaret Cancer Center
Toronto, Ontario, Canada
PVI, PeerView Institute for Medical Education
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Incyte Corporation.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Please visit our other symposia on AML, www.peerviewpress.com/AMLBMT, fungal infections, www.peerviewpress.com/infectionsHCT, hodgkin lymphoma, www.peerviewpress.com/HL17, and myeloma www.peerviewpress.com/MFBMT